Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms. An overview of the ultimate promising experimental drugs to manage glaucoma has been provided. In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors. The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.

Novel therapeutics in glaucoma management

BUCOLO, CLAUDIO;PLATANIA, CHIARA BIANCA MARIA;DRAGO, Filippo;REIBALDI, MICHELE;BONFIGLIO, VINCENZA;AVITABILE, Teresio;UVA, Maurizio Giacinto
2017-01-01

Abstract

Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms. An overview of the ultimate promising experimental drugs to manage glaucoma has been provided. In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors. The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.
Rho kinase inhibitors; anti-glaucoma drugs; dopamine ligands; glaucoma; histone deacetylase inhibitors; intraocular pressure; nitric oxide; purinergic ligands; retinal ganglion cells
File in questo prodotto:
File Dimensione Formato  
Novel Therapeutics in Glaucoma Management .pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Dimensione 548.22 kB
Formato Adobe PDF
548.22 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/313397
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 24
social impact